Updated Jul 16, 2026
RA CAPITAL MANAGEMENT, L.P. has filed 37 SEC Form 4 filings across 19 companies in the last 90 days — active on both sides. Lifetime open-market purchases: $992.24M. Lifetime open-market sales: $64.09M. Historical track record: 4/5 stars across 21 tracked purchases.
| Role | Insider |
|---|
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★★★★☆ (4/5) |
|---|---|
| Total purchases tracked | 21 |
| Purchases with forward-return data | 21 |
| 30-day win rate | 7143% |
| 90-day win rate | 5238% |
| Avg 5-day return | +805.19% |
| Avg 30-day return | +789.30% |
| Avg 90-day return | +559.11% |
| Best 30-day return | +4265.54% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-14 | ARTV | Artiva Biotherapeutics, Inc. | P — Open-market purchase | 6.6K | $8.94 | $59K |
| 2026-07-14 | ARTV | Artiva Biotherapeutics, Inc. | P — Open-market purchase | 15.1K | $8.97 | $135K |
| 2026-06-29 | ARTV | Artiva Biotherapeutics, Inc. | P — Open-market purchase | 1.9K | $8.98 | $17K |
| 2026-06-29 | ARTV | Artiva Biotherapeutics, Inc. | P — Open-market purchase | 31.0K | $8.88 | $275K |
| 2026-06-22 | HOWL | Werewolf Therapeutics, Inc. | S — Open-market sale | 27.7K | $0.35 | $10K |
| 2026-06-22 | HOWL | Werewolf Therapeutics, Inc. | S — Open-market sale | 389.2K | $0.35 | $136K |
| 2026-06-17 | COAG | Hemab Therapeutics Holdings, Inc. | P — Open-market purchase | 61.5K | $24.98 | $1.54M |
| 2026-06-17 | COAG | Hemab Therapeutics Holdings, Inc. | P — Open-market purchase | 6.1K | $24.89 | $153K |
| 2026-06-16 | ARTV | Artiva Biotherapeutics, Inc. | P — Open-market purchase | 124.9K | $8.89 | $1.11M |
| 2026-06-16 | ARTV | Artiva Biotherapeutics, Inc. | P — Open-market purchase | 15.4K | $8.99 | $139K |
| 2026-06-16 | ARTV | Artiva Biotherapeutics, Inc. | P — Open-market purchase | 391.0K | $8.57 | $3.35M |
| 2026-06-16 | HOWL | Werewolf Therapeutics, Inc. | S — Open-market sale | 9.9K | $0.37 | $4K |
| 2026-06-16 | HOWL | Werewolf Therapeutics, Inc. | S — Open-market sale | 139.7K | $0.37 | $52K |
| 2026-06-16 | HOWL | Werewolf Therapeutics, Inc. | S — Open-market sale | 8.6K | $0.39 | $3K |
| 2026-06-16 | HOWL | Werewolf Therapeutics, Inc. | S — Open-market sale | 120.2K | $0.39 | $47K |
| 2026-06-16 | HOWL | Werewolf Therapeutics, Inc. | S — Open-market sale | 11.3K | $0.40 | $5K |
| 2026-06-16 | HOWL | Werewolf Therapeutics, Inc. | S — Open-market sale | 159.1K | $0.40 | $64K |
| 2026-06-15 | PBLS | Parabilis Medicines, Inc. | P — Open-market purchase | 1.46M | $20.00 | $29.21M |
| 2026-06-15 | PBLS | Parabilis Medicines, Inc. | P — Open-market purchase | 19.73M | $20.00 | $394.57M |
| 2026-06-15 | PBLS | Parabilis Medicines, Inc. | J — Other acquisition / disposition | 1.19M | — |
RA CAPITAL MANAGEMENT, L.P. is a corporate insider — currently tracked as Insider of Artiva Biotherapeutics, Inc. (ARTV). InsiderAlpha tracks every SEC Form 4 filing in real time.
37 primary Form 4 filings in the last 90 days, covering 19 companies.
Recorded transactions: 51 open-market purchases ($992.24M) and 51 open-market sales ($64.09M) across all tracked filings.
Across 21 tracked purchases, RA CAPITAL MANAGEMENT, L.P. averaged +789.3% avg 30-day return with a 7143% 30-day win rate. InsiderAlpha rates the track record at 4/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live RA CAPITAL MANAGEMENT, L.P. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.